Download the AMCP Engagement Framework at AMCP.org for Payers and Patient Organizations to find various resources, tools, examples, and instructions to guide payers and patient organizations in opening lines of communication to assist with incorporating the patient’s voice in decision-making processes.
Download the AMCP Engagement Framework at AMCP.org for Payers and Patient Organizations to find various resources, tools, examples, and instructions to guide payers and patient organizations in opening lines of communication to assist with incorporating the patient’s voice in decision-making processes.
Prescription digital therapeutics (PDTs) are health software, available by prescription only, intended to treat or alleviate a disease, disorder, condition, or injury by generating and delivering a medical intervention that has a demonstrable positive therapeutic impact on a patient’s health.
PDTs offer significant promise in treating certain conditions and improving access to care, but participants
agreed that a new modality requires new approaches to coverage. This brief is intended to help prepare the American health care system to begin covering PDTs.
Host Fred Goldstein invites Jennifer Mathieu, Senior Vice President, Professional & Government Affairs to discuss the Prescription Digital Therapeutics Act, the Medicaid MVPs for Patient Act and other AMCP legislative priorities.
In the AMCP Legislative Days 2024 Booklet, learn about AMCP’s position on legislation impacting managed care pharmacy, how to talk to Members of Congress and their staff, and helpful tips for engaging in effective dialogue.
Access the AMCP Legislative Days 2024 Education Slides, to learn the terminology most associated with a Member of Congress and understand key advocacy vocabulary to help explain AMCP’s positions on the the Access to Prescription Digital Therapeutics Act of 2023 (S. 723/H.R. 1458) and the Medicaid VBPs for Patients (MVP) Act (H.R. 2666).